Shan X, Yang L, Gao X
PeerJ. 2024; 12:e18220.
PMID: 39376230
PMC: 11457875.
DOI: 10.7717/peerj.18220.
Aloran A, Jarrah S, Ahmed F, AbuRuz M
Acute Crit Care. 2024; 39(3):430-438.
PMID: 39266278
PMC: 11392702.
DOI: 10.4266/acc.2023.01053.
Addo B, Agyeman W, Ibrahim S, Berchie P
Am J Cardiovasc Drugs. 2024; 24(6):753-773.
PMID: 39261443
DOI: 10.1007/s40256-024-00669-x.
Tanashat M, Manasrah A, Abouzid M
Eur J Clin Pharmacol. 2024; 80(7):951-963.
PMID: 38498097
DOI: 10.1007/s00228-024-03660-2.
Ali A, Mazroua M, ElSaban M, Najam N, Kothari A, Mansoor T
Glob Heart. 2023; 18(1):45.
PMID: 37636033
PMC: 10453961.
DOI: 10.5334/gh.1258.
Epidemiology and management of heart failure with reduced ejection fraction in a Tunisian university hospital.
Drissa M, Drissa H, Helali S, Oughlani K, Farah A, Chebbi M
Cardiovasc J Afr. 2023; 34(2):68-72.
PMID: 37132406
PMC: 10512042.
DOI: 10.5830/CVJA-2018-070.
Predictive Effect of Triglyceride-Glucose Index on Adverse Prognostic Events in Patients with Type 2 Diabetes Mellitus and Ischemic Cardiomyopathy.
Abuduaini B, Yang L, Jiamali N, Seyiti Z, Shan X, Gao X
Diabetes Metab Syndr Obes. 2023; 16:1093-1107.
PMID: 37114217
PMC: 10126725.
DOI: 10.2147/DMSO.S408766.
An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats.
He L, Ma S, Zuo Q, Zhang G, Wang Z, Zhang T
Front Pharmacol. 2022; 13:856386.
PMID: 35370704
PMC: 8964360.
DOI: 10.3389/fphar.2022.856386.
The Value of Echocardiography Combined with NT-pro BNP Level in Assessment and Prognosis of Diastolic Heart Failure.
Chen S, Zhou Y, Wu X, Shi S, Wu H, Li P
Comput Math Methods Med. 2022; 2022:2102496.
PMID: 35169397
PMC: 8841100.
DOI: 10.1155/2022/2102496.
Photobiomodulation therapy combined with carvedilol attenuates post-infarction heart failure by suppressing excessive inflammation and oxidative stress in rats.
Grandinetti V, Carlos F, Antonio E, de Oliveira H, Neves Dos Santos L, Yoshizaki A
Sci Rep. 2019; 9(1):9425.
PMID: 31263132
PMC: 6603025.
DOI: 10.1038/s41598-019-46021-1.
Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim Y, Han S, Kim D, Lee K, Kim H
Cardiovasc Diabetol. 2018; 17(1):91.
PMID: 29935543
PMC: 6015464.
DOI: 10.1186/s12933-018-0737-5.
Management protocols for chronic heart failure in India.
Mishra S, Mohan J, Nair T, Chopra V, Harikrishnan S, Guha S
Indian Heart J. 2018; 70(1):105-127.
PMID: 29455764
PMC: 5903070.
DOI: 10.1016/j.ihj.2017.11.015.
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Lytvyn Y, Bjornstad P, Udell J, Lovshin J, Cherney D
Circulation. 2017; 136(17):1643-1658.
PMID: 29061576
PMC: 5846470.
DOI: 10.1161/CIRCULATIONAHA.117.030012.
